In ARCHES-2 study (n=204) of zodasiran in patients with mixed dyslipidemia (fasting TGs: 150-499 mg/dL & either LDL-cholesterol >70 mg/dL or non-HDL-cholesterol >100 mg/dL), two doses of 50 mg, 100 mg, or 200 mg of zodasiran Q12W silenced ANGPTL3 expression & decreased atherogenic lipoproteins
Zodasiran administration resulted in substantial reductions of ANGPTL3 up to -71% at wk 8, TGs up to 59% at wk 16, and LDL-C up to -32% at wk 16.
ARO-ANG3 was associated with a relative reduction in liver fat fraction at wk24, with no AEs related to liver function test changes reported. ARO-ANG3 TEAEs are consistent with patient population and with associated underlying comorbidities
Ref: Arrowhead | Image: Arrowhead
Related News:- Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
